Company intelligence / Profile preview
Chongqing Peg-Bio Biopharm Co., Ltd.
Beibei District/Liangjiang New Area, Chongqing Shi, Chinalinkedin.com ↗
- Ownership
- Private
- Employees
- ~75
- Development stage
- Phase 3
01
Overview
Developing long-acting biologics with one NDA submission (PB-119 for T2DM) and multiple clinical-stage candidates including oncology programs. Partnering with Huadong Medicine on biosimilars.
- Therapeutic areas
- GastroenterologyEndocrinologyOncologyHematology
- Modalities
- Recombinant proteinsPeptidesBiosimilars
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Huadong Medicine(Semaglutide biosimilar development)[8][9]四环医药/Jilin Sihuan Pharma("Insulin Project")[10]
Beyond the preview
Go deeper on Chongqing Peg-Bio Biopharm Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Chongqing Peg-Bio Biopharm Co., Ltd..